| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ALERISLIFE Aktie jetzt für 0€ handeln |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FRESENIUS | 47,570 | -1,27 % | DEUTSCHE BANK RESEARCH stuft Fresenius SE auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Fresenius mit einem Kursziel von 56 Euro auf "Buy" belassen. Analyst Falko Friedrichs lobte in seiner am Donnerstag vorliegenden... ► Artikel lesen | |
| CARL ZEISS MEDITEC | 25,640 | -0,93 % | INDEX-MONITOR: Lufthansa verpasst Dax-Rückkehr - Nur Wechsel in MDax und SDax | ZUG (dpa-AFX) - Die Aktien von Lufthansa haben die Rückkehr in den deutschen Leitindex Dax verpasst. Wie der zur Deutschen Börse gehörende Index-Anbieter Stoxx am späten Mittwochabend mitteilte, bleibt... ► Artikel lesen | |
| M1 KLINIKEN | 15,900 | 0,00 % | M1 Kliniken schließt Verkauf von Haemato Pharm ab | Die M1 Kliniken AG hat den Verkauf der Haemato Pharm GmbH über ihre Mehrheitsbeteiligung Haemato AG an die Phoenix Group mit Wirkung zum Ablauf des 31. Januar 2026 abgeschlossen. Sämtliche Vollzugsbedingungen... ► Artikel lesen | |
| DEXCOM | 62,85 | +0,34 % | Kevin Sayer returns from leave of absence to chair Dexcom board | ||
| PLUS THERAPEUTICS | 0,309 | +2,25 % | Plus Therapeutics Inc.: Plus Therapeutics Announces New Category III CPT Code for Convection-Enhanced Delivery Used with REYOBIQ | HOUSTON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ: PSTV) (the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals... ► Artikel lesen | |
| CARDINAL HEALTH | 192,50 | +0,36 % | Cardinal Health, Inc. (CAH): A Bull Case Theory | ||
| DAVITA | 129,80 | -2,33 % | DaVita Celebrates 20 Years on Fortune's List of World's Most Admired Companies | Two decades of recognition underscore leadership in clinical innovation, employer strategy NORTHAMPTON, MA / ACCESS Newswire / February 26, 2026 / DaVita, a leading provider of comprehensive kidney... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc.: Evofem Reports Financial Results for Third Quarter of 2025, Provides Business Update | -- Increased Net Sales 10% While Lowering Operating Expenses 42% vs. Prior Year Quarter --
-- Delivered $1.0 Million of Operating Income in Q3 2025 --
SAN DIEGO... ► Artikel lesen | |
| DENTSPLY SIRONA | 11,455 | -0,91 % | Dentsply Sirona Q4 Loss Narrows | WASHINGTON (dpa-AFX) - Dentsply Sirona Inc. (XRAY) Thursday reported a fourth-quarter net loss of $146 million or $0.74 per share, compared to $430 million or $2.16 per share last year.Adjusted... ► Artikel lesen | |
| CENTENE | 38,620 | -0,09 % | Centene Guides FY26 Adj. EPS Above Estimates As Q4 Results Top Estimates | WASHINGTON (dpa-AFX) - While reporting financial results for the fourth quarter on Friday, healthcare company Centene Corp. (CNC) initiated its earnings, adjusted earnings and total revenue... ► Artikel lesen | |
| CYTOSORBENTS | 0,650 | -4,27 % | Cytosorbents Corp: CytoSorbents Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Results and Business Update | Fourth quarter and Full-Year 2025 revenue are expected to be approximately $9.2 million and $37.0 million, respectively, with expected Q4 gross margins in the range... ► Artikel lesen | |
| COOPER COMPANIES | 70,50 | 0,00 % | Cooper Companies' Earnings Outlook | ||
| EKSO BIONICS | 10,700 | 0,00 % | Applied Digital Corporation: Applied Digital to Spin Out Cloud Business, Proposes Business Combination with EKSO to Launch ChronoScale | DALLAS, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Applied Digital (NASDAQ: APLD), a designer, builder, and operator of high-performance, sustainably engineered data centers and colocation services for artificial... ► Artikel lesen | |
| FULGENT GENETICS | 12,400 | +2,48 % | Fulgent Genetics forecasts $350M 2026 revenue and 53% AP growth as Bako, StrataDx acquisitions reshape customer mix | ||
| IMUNON | 2,860 | -5,92 % | Imunon, Inc.: IMUNON Reports Third Quarter 2025 Financial Results and Provides Business Update | R&D Day showcased remarkable Investigator optimism, continued strengthening supportive data, and significant progress with Phase 3 OVATION 3 Study in pursuit of first frontline immunotherapy for advanced... ► Artikel lesen |